Fasinumab is a monoclonal antibody designed to target and inhibit nerve growth factor (NGF), playing a key role in pain signaling pathways. The Anti-NGF / bNGF Reference Antibody (fasinumab) serves as a research tool mimicking this therapeutic antibody. It has been investigated primarily for the treatment of chronic pain conditions, especially those involving osteoarthritis and chronic low back pain. By blocking NGF activity, fasinumab reduces the sensitization of pain pathways, leading to significant pain relief in patients who may not respond adequately to traditional analgesics like NSAIDs or opioids.

Clinical studies have shown that fasinumab can improve pain and physical function in osteoarthritis patients, particularly those with knee involvement. It has also been studied in interstitial cystitis and other chronic pain disorders. Due to its targeted mechanism, it offers a potential alternative for patients seeking non-opioid pain management. However, safety concerns, particularly related to joint damage in some patients, have limited its long-term use and led to careful patient selection in clinical development.